Sera Prognostics, Inc. (The Pregnancy Company)

Sera Prognostics, Inc. is a women's health diagnostics company dedicated to improving maternal and neonatal health outcomes. Headquartered in Salt Lake City, Utah, the company's core mission is to provide early and pivotal pregnancy biomarker information to healthcare providers and patients, with the goal of reducing healthcare delivery costs.

The company leverages a proprietary proteomics and bioinformatics platform to discover, develop, and commercialize blood-based biomarker tests. Its flagship commercial product is the PreTRM® test, a non-invasive blood test administered between weeks 18 and 20 of gestation. This test predicts the individualized risk of spontaneous preterm birth in asymptomatic singleton pregnancies, enabling earlier proactive interventions. Sera Prognostics also maintains a pipeline of diagnostic tests for other pregnancy complications, including preeclampsia and fetal growth restriction.

Recent notable developments include the publication of the landmark PRIME randomized trial in early 2026, which demonstrated that the PreTRM test, combined with targeted interventions, significantly reduced early preterm births and neonatal complications. The company is actively expanding its commercial reach through new partnerships and engaging with payers to secure broader coverage for its diagnostic solutions. Zhenya Lindgardt serves as the President and Chief Executive Officer.